The estimated Net Worth of Robert J Cindrich is at least $922 millier dollars as of 16 November 2020. Robert Cindrich owns over 9,440 units of Mylan NV stock worth over $557,365 and over the last 12 years he sold MYL stock worth over $0. In addition, he makes $365,006 as Non-Executive Independent Director at Mylan NV.
Robert has made over 10 trades of the Mylan NV stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 9,440 units of MYL stock worth $149,624 on 16 November 2020.
The largest trade he's ever made was exercising 9,440 units of Mylan NV stock on 16 November 2020 worth over $149,624. On average, Robert trades about 2,757 units every 181 days since 2012. As of 16 November 2020 he still owns at least 35,165 units of Mylan NV stock.
You can see the complete history of Robert Cindrich stock trades at the bottom of the page.
Hon. Robert J. Cindrich serves as Non-Executive Independent Director of the Company. Since February 2011, Judge Cindrich has been president of Cindrich Consulting, LLC, a business and healthcare consulting company that advises clients on corporate governance, compliance and business strategies. Since May 2015, Judge Cindrich has served on the Advisory Council of Innovu, LLC, a health and risk management consulting company. From October 1, 2013, through January 31, 2014, he served as interim general counsel for United States Steel Corporation (“U.S. Steel”) (NYSE: X), an integrated steel producer of flat-rolled and tubular products. Judge Cindrich joined Schnader Harrison Segal & Lewis (“Schnader”), a law firm, as legal counsel in April 2013 and took a temporary leave of absence on October 1, 2013, to join U.S. Steel as interim general counsel, returning to Schnader after his time there and remaining until December 2017. In May 2012, he joined the board of directors of Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), which provides healthcare information technology solutions, where he served until April 2015. From 2011 through 2012, Judge Cindrich served as a senior advisor to the Office of the President of the University of Pittsburgh Medical Center (“UPMC”), an integrated global health enterprise. From 2004 through 2010, Judge Cindrich was a senior vice president and the chief legal officer of UPMC. From 1994 through January 2004, Judge Cindrich served as a judge on the U.S. District Court for the Western District of Pennsylvania. Prior to that appointment, he was an attorney in government and private practice, including positions as the U.S. Attorney for the Western District of Pennsylvania and as the Allegheny County Assistant Public Defender and Assistant District Attorney. Judge Cindrich will not serve as a director of Viatris upon closing of the Combination. Judge Cindrich’s qualifications to serve on Mylan’s Board include, among others, his knowledge and expertise regarding legal and regulatory matter
As the Non-Executive Independent Director of Mylan NV, the total compensation of Robert Cindrich at Mylan NV is $365,006. There are 8 executives at Mylan NV getting paid more, with Heather Bresch having the highest compensation of $18,509,300.
Robert Cindrich is 76, he's been the Non-Executive Independent Director of Mylan NV since 2016. There are no older and 12 younger executives at Mylan NV.
Robert's mailing address filed with the SEC is BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, , HATFIELD, HERTFORDSHIRE, X0, AL10 9UL.
Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher et Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Mylan NV executives and other stock owners filed with the SEC include: